BAM
SMMT icon

Bosun Asset Management’s Summit Therapeutics SMMT Stock Holding History

Bosun Asset Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-24,593
Closed -$474K – 223
2025
Q1 		$474K Buy
24,593
+9,249
+60% +$186K 0.2% 123
2024
Q4 		$274K Sell
15,344
-10,943
-42% -$212K 0.12% 167
2024
Q3 		$576K Buy
+26,287
New +$368K 0.27% 102

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Bosun Asset Management's SMMT Position: Q2 2025 in Review

Bosun Asset Management sold out of Summit Therapeutics (SMMT) in Q2 2025, closing a stake of 24,593 shares — an estimated $474K sold.

Bosun Asset Management first reported a position in SMMT in Q3 2024 and held it in 3 quarters. The position peaked at $576K in Q3 2024. 238 funds tracked by Wall St. Rank hold SMMT as of Q2 2025.

  • Bosun Asset Management reported no remaining Summit Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Bosun Asset Management sold 24,593 Summit Therapeutics shares in Q2 2025, an estimated $474K.
  • Bosun Asset Management first reported a position in Summit Therapeutics in Q3 2024 and held it in 3 quarters.
  • Bosun Asset Management's Summit Therapeutics position peaked at $576K in Q3 2024.
  • 238 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2025.

Based on Bosun Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.